{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:41Z","timestamp":1753890701650,"version":"3.41.2"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:00:00Z","timestamp":1549324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00040","type":"journal-article","created":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T04:15:06Z","timestamp":1549340106000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Three Therapeutic Strategies: Cinacalcet, Paricalcitol or Both in Secondary Hyperparathyroidism Treatment in Hemodialysed Patients During 1-Year Observational Study\u2014A Comparison"],"prefix":"10.3389","volume":"10","author":[{"given":"Jacek","family":"Zawierucha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek S.","family":"Malyszko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Prystacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech P.","family":"Marcinkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Dryl-Rydzynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,2,5]]},"reference":[{"key":"B1","first-page":"1","article-title":"Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","author":"Kidney","year":"2017","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12882-015-0006-8","article-title":"Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study","volume":"16","author":"Messa","year":"2015","journal-title":"BMC Nephrol."},{"key":"B3","unstructured":"2018"},{"key":"B4","unstructured":"2018"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/ATVBAHA.114.303637","article-title":"Parathyroid hormone","volume":"34","author":"Goettsch","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3122\/jabfm.2009.05.090026","article-title":"Secondary hyperparathyroidoism, pathophysiology and treatment","volume":"5","author":"Saliba","year":"2009","journal-title":"JABFM"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"Clin J Am Soc Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2215\/CJN.01040308","article-title":"Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results","volume":"3","author":"Fishbane","year":"2008","journal-title":"Clin J Am Soc Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"Cunningham","year":"2005","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"J Am Soc Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfm534","article-title":"Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients","volume":"23","author":"Fukagawa","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"B14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000357677","article-title":"Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients: A German-Austrian, single-arm, open- label, prospective, noninterventional, observational study","volume":"126","author":"Biggar","year":"2014","journal-title":"Nephr Clin Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1471-2369-13-159","article-title":"Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients","volume":"27","author":"Izquierdo","year":"2012","journal-title":"BMC Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/0886022X.2011.647298","article-title":"Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study","volume":"3","author":"Tonbul","year":"2012","journal-title":"Ren Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1542-4758.2010.00514.x","article-title":"Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: responsiveness is related to parathyroid gland size","volume":"15","author":"Vulpio","year":"2011","journal-title":"Hemodial Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/00365599.2011.553738","article-title":"Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: An observational study","volume":"45","author":"Fernstr\u00f6m","year":"2011","journal-title":"Scand J Urol Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1038\/sj.ki.5001981","article-title":"Paricalcitol therapy for secondary hyperparathyroidism in patients on maintenance hemodialysis previously treated with calcitriol: a single-center crossover study","volume":"70","author":"Mittman","year":"2006","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1038\/ki.2010.191","article-title":"Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study","volume":"78","author":"Mittman","year":"2010","journal-title":"Kidney Int"},{"key":"B21","first-page":"315","article-title":"A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease","volume":"56","author":"Lindberg","year":"2001","journal-title":"Clin Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","article-title":"Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism","volume":"38","author":"Llach","year":"2001","journal-title":"Am J Kidney Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000346846","article-title":"Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis","volume":"37","author":"Duranton","year":"2013","journal-title":"Am J Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/ndt\/gfs108","article-title":"VDRA therapy is associated with improved survival in dialysis patients with serum intact iPTH \u2264 150 pg\/mL: results of the Italian FARO Survey","volume":"27","author":"Cozzolino","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1093\/ndt\/gfr531","article-title":"Paricalcitol versus cinacalcet plus low\u2013dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1093\/ndt\/gfs018","article-title":"Paricalcitol versus cinacalcet plus low\u2013dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study","volume":"27","author":"Ketteler","year":"2012","journal-title":"Nephrol Dial Transplant."},{"key":"B27","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1093\/ndt\/gfu011","article-title":"Paricalcitol or cinacalcet \u2013 centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: Results of the IMPACT\u2013SHPT study","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40261-013-0151-4","article-title":"Cost effectiveness of paricalcitol versus cinacalcet with low\u2013dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA","volume":"34","author":"Sharma","year":"2014","journal-title":"Clin Drug Investig."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3111\/13696998.2013.823092","article-title":"Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low\u2013dose vitamin D in hemodialysis patients","volume":"16","author":"Sharma","year":"2013","journal-title":"J Med Econ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate","volume":"1","author":"Chertow","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study","volume":"28","author":"Ure\u00f1a-Torres","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/ndt\/gfn026","article-title":"Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism","volume":"23","author":"Block","year":"2008","journal-title":"Nephrol Dial Transplant."},{"key":"B33","doi-asserted-by":"publisher","first-page":"c151","DOI":"10.1159\/000319781","article-title":"Comparative effectiveness of paricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"117","author":"Schumock","year":"2011","journal-title":"Nephron Clin Pract."},{"key":"B34","first-page":"229","article-title":"Treatment of secondary hyperparathyroidism in hemodialyzed patients \u2013 paricalcitol with or without cinacalcet","volume":"73","author":"Zawierucha","year":"2016","journal-title":"Przegl Lek."},{"key":"B35","doi-asserted-by":"publisher","first-page":"840","DOI":"10.20452\/pamw.4124","article-title":"Treatment of secondary hyperparathyroidism with paricalcitol with or without cinacalcet in hemodialysis patients","volume":"127","author":"Zawierucha","year":"2017","journal-title":"Pol Arch Intern Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2215\/CJN.04720416","article-title":"Blood calcification propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial","volume":"12","author":"Pasch","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: the Evaluation of Cinacalcet HCI Therapy to Lower Cardiovascular Events (EVOLVE) trial","volume":"10","author":"Parfey","year":"2015","journal-title":"Clin J Am Soc Nephrol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial","volume":"98","author":"Parfrey","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ki.2009.188","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease \u2013 mineral and bone disorder (CKD\u2013MBD)","volume":"76","author":"Kidney","year":"2009","journal-title":"Kidney Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1096\/fj.12-208975","article-title":"In vivo evidence for a novel pathway of vitamin D metabolism initiated by P450scc and modified by CYP27B1","volume":"26","author":"Slominski","year":"2012","journal-title":"FASEB J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jsbmb.2014.11.010","article-title":"Novel activities of CYP11A1 and their potential physiological significance","volume":"151","author":"Slominski","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"14875","DOI":"10.1038\/srep14875","article-title":"Detection of novel CYP11A1-derived secosteroids in the human epidermis and serum and pig adrenal gland","volume":"5","author":"Slominski","year":"2015","journal-title":"Sci Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"11434","DOI":"10.1038\/s41598-017-10202-7","article-title":"Characterization of a new pathway that activates lumisterol in vivo to biologically active hydroxylumisterols","volume":"7","author":"Slominski","year":"2017","journal-title":"Sci Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T11:26:29Z","timestamp":1662895589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,5]]},"references-count":45,"alternative-id":["10.3389\/fendo.2019.00040"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00040","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2019,2,5]]},"article-number":"40"}}